Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Laparoscopic-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric Cancer
Not Applicable
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Procedure: laparoscopy-assisted distal gastrectomy GroupProcedure: Totally laparoscopic distal gastrectomy
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 202
- Registration Number
- NCT05541783
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
Phase 3
Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Drug: VICDrug: Bevacizumab Plus Chemotherapy
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 78
- Registration Number
- NCT05540951
- Locations
- 🇨🇳
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
Laparoscopic vs Open Total Gastrectomy for Gastric Cancer
Not Applicable
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Procedure: Total Gastrectomy
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT05537129
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Phase 2
Recruiting
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05531123
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Radiation: Preoperative radiotherapyRadiation: Postmastectomy radiotherapy
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT05512286
- Locations
- 🇨🇳
Guangxi Provincial Cancer Hospital, Nanning, Guangxi, China
🇨🇳Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hunan Provincial Cancer Hospital, Changsha, Hunan, China
Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
Completed
- Conditions
- Breast Cancer
- Interventions
- Other: no intervention
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1299
- Registration Number
- NCT05510037
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Application of ICG Fluorescence Cholangiography in Laparoscopic Living Donor Left Lateral Sectionectomy
Not Applicable
Completed
- Conditions
- Living Donor Liver Transplantation
- Interventions
- Procedure: indocyanine green (ICG) fluorescence cholangiography
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 85
- Registration Number
- NCT05506020
PD-1 Inhibitors With or Without Radiation in Advanced Melanoma
Phase 2
Not yet recruiting
- Conditions
- the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma
- Interventions
- Radiation: Radiation
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 92
- Registration Number
- NCT05498805
- Locations
- 🇨🇳
Fudan University Shanghai Cencer Center, Shanghai, Shanghai, China
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
Phase 2
Not yet recruiting
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 294
- Registration Number
- NCT05489848
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT05483543
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath